Recent Updates
Recently added Catalysts
AFMD

Affimed to Present at the Jefferies Global Healthcare Conference

Key Takeaway: Accessibility: Skip TopNav Affimed to Present at the Jefferies Global Healthcare Conference May 30, 2018 05:00 ET Heidelberg, Germany, May 30, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted c

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Full Press Release Details

Accessibility: Skip TopNav

Affimed to Present at the Jefferies Global Healthcare Conference

May 30, 2018 05:00 ET
Heidelberg, Germany, May 30, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at 4:30 pm ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
Last updated: May 30, 2018